Differences in Incidence, Nature of Symptoms, and Duration of Long COVID Among Hospitalised Migrant and Non-migrant Patients in the Netherlands: a Retrospective Cohort Study

Overview

Journal Lancet Reg Health Eur

Specialty Health Services

Date 2023 Jun 1

PMID 37261215

Authors

Felix Patience Chilunga

Brent Appelman

Michele van Vugt

Kirsten Kalverda

Patrick Smeele

Josien van Es

Willem Joost Wiersinga

Mikael Rostila

Maria Prins

Karien Stronks

Marie Norredam

Charles Agyemang

Affiliations

Soon will be listed here.

Abstract

Background: Comprehensive data on long COVID across ethnic and migrant groups are lacking. We investigated incidence, nature of symptoms, clinical predictors, and duration of long COVID among COVID-19 hospitalised patients in the Netherlands by migration background (Dutch, Turkish, Moroccan, and Surinamese origin, Others).

Methods: We used COVID-19 admissions and follow up data (January 2021-July 2022) from Amsterdam University Medical Centers. We calculated long COVID incidence proportions per NICE guidelines by migration background and assessed for clinical predictors via robust Poisson regressions. We then examined associations between migration background and long COVID using robust Poisson regressions and adjusted for derived clinical predictors, and other biologically relevant factors. We also assessed long COVID symptom persistence at one-year post-discharge.

Findings: 1886 patients were included. 483 patients had long COVID (26%, 95% CI 24-28%) at 12 weeks post-discharge. Symptoms like dizziness, joint pain, insomnia, and headache varied by migration background. Clinical predictors of long COVID were female sex, hospital admission duration, intensive care unit admission, and receiving oxygen, or corticosteroid therapy. Long COVID risk was higher among patients with migration background than Dutch origin patients after adjustments for derived clinical predictors, age, smoking, vaccination status, comorbidities and remdesivir treatment. Only 14% of long COVID symptoms persisted at one-year post-discharge.

Interpretation: There are significant differences in occurrence, nature of symptoms, and duration of long COVID by migration background. Studies assessing the spectrum of functional limitation and access to post-COVID healthcare are needed to help plan for appropriate and accessible healthcare interventions.

Funding: The Amsterdam UMC COVID-19 biobank is supported by the Amsterdam UMC Corona Research Fund and the Talud Foundation (Stichting Talud). The current analyses were supported by the Novo Nordisk Foundation [NNF21OC0067528].

Citing Articles

Association between Mexican vaccination schemes and the duration of long COVID syndrome symptoms.

Rodriguez-Torres J, Romero-Ibarguengoitia M, Garza-Silva A, Rivera-Cavazos A, Hurtado-Cabrera M, Kalife-Assad R Sci Rep. 2025; 15(1):5301.

PMID: 39939334 PMC: 11821848. DOI: 10.1038/s41598-024-59954-z.

Long COVID and its risk factors in migrants: a nationwide register study from Sweden.

Cederstrom A, Mkoma G, Benfield T, Agyemang C, Norredam M, Rostila M BMC Med. 2025; 23(1):53.

PMID: 39875996 PMC: 11776292. DOI: 10.1186/s12916-025-03900-x.

Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health.

Fekete M, Lehoczki A, Szappanos A, Toth A, Mahdi M, Sotonyi P Geroscience. 2025; 47(1):745-779.

PMID: 39777702 PMC: 11872997. DOI: 10.1007/s11357-024-01487-4.

Novel biomarkers of mitochondrial dysfunction in Long COVID patients.

Szogi T, Borsos B, Masic D, Radics B, Bella Z, Banfi A Geroscience. 2024; .

PMID: 39495479 DOI: 10.1007/s11357-024-01398-4.

One-year trajectories of physical and mental health-related quality of life, fatigue and dyspnoea in COVID-19 survivors.

Schaap G, Davelaar J, Ten Klooster P, Doggen C, van der Palen J, Bode C Qual Life Res. 2024; 34(2):341-351.

PMID: 39425867 PMC: 11865161. DOI: 10.1007/s11136-024-03812-y.

References

Liu Y, Chen Y, Wang Q, Wang L, Jiang L, Yang Y . One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China: A Longitudinal Cohort Study. JAMA Neurol. 2022; 79(5):509-517. PMC: 8905512. DOI: 10.1001/jamaneurol.2022.0461. View

Coyer L, Boyd A, Schinkel J, Agyemang C, Galenkamp H, Koopman A . Differences in SARS-CoV-2 infections during the first and second wave of SARS-CoV-2 between six ethnic groups in Amsterdam, the Netherlands: A population-based longitudinal serological study. Lancet Reg Health Eur. 2021; 13:100284. PMC: 8668416. DOI: 10.1016/j.lanepe.2021.100284. View

Seessle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A . Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis. 2021; 74(7):1191-1198. PMC: 8394862. DOI: 10.1093/cid/ciab611. View

Collard D, Stronks K, Harris V, Coyer L, Brinkman K, Beudel M . Ethnic Differences in Coronavirus Disease 2019 Hospitalization and Hospital Outcomes in a Multiethnic Population in the Netherlands. Open Forum Infect Dis. 2022; 9(6):ofac257. PMC: 9129177. DOI: 10.1093/ofid/ofac257. View

Ballering A, van Zon S, Olde Hartman T, Rosmalen J . Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022; 400(10350):452-461. PMC: 9352274. DOI: 10.1016/S0140-6736(22)01214-4. View

Chilunga F, Stoeldraijer L, Agyemang C, Stronks K, Harmsen C, Kunst A . Inequalities in COVID-19 deaths by migration background during the first wave, interwave period and second wave of the COVID-19 pandemic: a closed cohort study of 17 million inhabitants of the Netherlands. J Epidemiol Community Health. 2022; . DOI: 10.1136/jech-2022-219521. View

Mathur R, Rentsch C, Morton C, Hulme W, Schultze A, Mackenna B . Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021; 397(10286):1711-1724. PMC: 8087292. DOI: 10.1016/S0140-6736(21)00634-6. View

Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy A . Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol. 2011; 11:40. PMC: 3079702. DOI: 10.1186/1471-2288-11-40. View

Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q . 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021; 9(7):747-754. PMC: 8099316. DOI: 10.1016/S2213-2600(21)00174-0. View

10.

Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale K . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022; 28(8):1706-1714. PMC: 9388369. DOI: 10.1038/s41591-022-01909-w. View

11.

Crook H, Raza S, Nowell J, Young M, Edison P . Long covid-mechanisms, risk factors, and management. BMJ. 2021; 374:n1648. DOI: 10.1136/bmj.n1648. View

12.

Guijarro C, Perez-Fernandez E, Gonzalez-Pineiro B, Melendez V, Goyanes M, Renilla M . Differential risk for COVID-19 in the first wave of the disease among Spaniards and migrants from different areas of the world living in Spain. Rev Clin Esp (Barc). 2021; 221(5):264-273. DOI: 10.1016/j.rceng.2020.10.005. View

13.

Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B . Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. JAMA Netw Open. 2021; 4(9):e2127403. PMC: 8482055. DOI: 10.1001/jamanetworkopen.2021.27403. View

14.

Raveendran A, Jayadevan R, Sashidharan S . Long COVID: An overview. Diabetes Metab Syndr. 2021; 15(3):869-875. PMC: 8056514. DOI: 10.1016/j.dsx.2021.04.007. View

15.

Kerkhoff T, Charlton B, Appelman B, van Vugt M, Wust R . Post COVID-19 condition: critical need for a clear definition and detailed pathophysiology. J Cachexia Sarcopenia Muscle. 2022; 13(6):2754-2756. PMC: 9745497. DOI: 10.1002/jcsm.13108. View

16.

Venkatesan P . NICE guideline on long COVID. Lancet Respir Med. 2021; 9(2):129. PMC: 7832375. DOI: 10.1016/S2213-2600(21)00031-X. View

17.

Thompson E, Williams D, Walker A, Mitchell R, Niedzwiedz C, Yang T . Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022; 13(1):3528. PMC: 9240035. DOI: 10.1038/s41467-022-30836-0. View

18.

Chen C, Haupert S, Zimmermann L, Shi X, Fritsche L, Mukherjee B . Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022; 226(9):1593-1607. PMC: 9047189. DOI: 10.1093/infdis/jiac136. View

19.

de Bruin S, Bos L, van Roon M, Tuip-de Boer A, Schuurman A, Koel-Simmelinck M . Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine. 2021; 67:103378. PMC: 8118723. DOI: 10.1016/j.ebiom.2021.103378. View

20.

Ramasamy S, Kolloli A, Kumar R, Husain S, Soteropoulos P, Chang T . Comprehensive Analysis of Disease Pathology in Immunocompetent and Immunocompromised Hosts following Pulmonary SARS-CoV-2 Infection. Biomedicines. 2022; 10(6). PMC: 9219777. DOI: 10.3390/biomedicines10061343. View